Business Description
BridgeBio Pharma Inc
NAICS : 325412
SIC : 2834
ISIN : US10806X1028
Total Employee Number:
839Compare
Compare
Traded in other countries / regions
BBIO.USA2CL.Germany1BBIO.Italy Index Membership
Russell 2000Russell 3000 IPO Date
2019-06-27Description
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.29 | |||||
Equity-to-Asset | -2.07 | |||||
Debt-to-Equity | -0.99 | |||||
Debt-to-EBITDA | -5.06 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -2.97 | |||||
Beneish M-Score | -1.49 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 70.7 | |||||
3-Year EBITDA Growth Rate | -2.1 | |||||
3-Year EPS without NRI Growth Rate | -7.4 | |||||
3-Year FCF Growth Rate | 6.3 | |||||
3-Year Book Growth Rate | -8.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 72.47 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 8.22 | |||||
9-Day RSI | 21.52 | |||||
14-Day RSI | 32.03 | |||||
3-1 Month Momentum % | 25.4 | |||||
6-1 Month Momentum % | 29.25 | |||||
12-1 Month Momentum % | 55.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.23 | |||||
Quick Ratio | 1.17 | |||||
Cash Ratio | 0.81 | |||||
Days Inventory | 286.03 | |||||
Days Sales Outstanding | 81.14 | |||||
Days Payable | 252.8 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.9 | |||||
Shareholder Yield % | -1.05 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 94.44 | |||||
Operating Margin % | -67.01 | |||||
Net Margin % | -97.03 | |||||
EBITDA Margin % | -69.1 | |||||
FCF Margin % | -61.4 | |||||
OCF Margin % | -60.92 | |||||
ROA % | -61.74 | |||||
ROIC % | -107.65 | |||||
3-Year ROIIC % | -27.49 | |||||
ROC (Joel Greenblatt) % | -1627.45 | |||||
ROCE % | -77.41 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 286.86 | |||||
PS Ratio | 20.8 | |||||
EV-to-EBIT | -33.55 | |||||
EV-to-Forward-EBIT | -103.07 | |||||
EV-to-EBITDA | -33.89 | |||||
EV-to-Forward-EBITDA | -115.6 | |||||
EV-to-Revenue | 23.42 | |||||
EV-to-Forward-Revenue | 9.75 | |||||
EV-to-FCF | -38.15 | |||||
Price-to-GF-Value | 0.5 | |||||
Earnings Yield (Greenblatt) % | -2.98 | |||||
FCF Yield % | -2.93 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BBIO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BridgeBio Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 713.069 | ||
| EPS (TTM) ($) | -3.57 | ||
| Beta | 0.6402 | ||
| 3-Year Sharpe Ratio | 0.82 | ||
| 3-Year Sortino Ratio | 1.65 | ||
| Volatility % | 35.3 | ||
| 14-Day RSI | 32.03 | ||
| 14-Day ATR ($) | 2.425726 | ||
| 20-Day SMA ($) | 79.533 | ||
| 12-1 Month Momentum % | 55.61 | ||
| 52-Week Range ($) | 48.78 - 93.415 | ||
| Shares Outstanding (Mil) | 195.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BridgeBio Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BridgeBio Pharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-24 16:30 | In 169 days | ||
| Annual report for 2026 | 2027-02-24 | In 168 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-24 | In 168 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-29 16:30 | In 51 days | ||
| Third quarter earnings results for 2026 | 2026-10-29 | In 50 days | ||
| Guidance call for 2026 | 2026-09-23 09:40 | In 15 days | ||
| Morgan Stanley 24th Annual Global Healthcare Conference | 2026-09-15 10:00 | In 7 days | ||
| Guidance call for 2026 | 2026-09-10 09:10 | In 2 days | ||
| 21st Annual Wells Fargo Healthcare Conference | 2026-09-09 01:30 | In 1 day | ||
| Second quarter earnings conference call for 2026 | 2026-08-10 16:30 | 84.48 (+0.91%) |
Show
Entries
BridgeBio Pharma Inc Frequently Asked Questions
What is BridgeBio Pharma Inc(BBIO)'s stock price today?
The current price of BBIO is $76.31. The 52 week high of BBIO is $93.42 and 52 week low is $48.78.
When is next earnings date of BridgeBio Pharma Inc(BBIO)?
The next earnings date of BridgeBio Pharma Inc(BBIO) is 2026-10-29 Est..
Does BridgeBio Pharma Inc(BBIO) pay dividends? If so, how much?
BridgeBio Pharma Inc(BBIO) does not pay dividend.
Guru Commentaries on NAS:BBIO
Invesco Discovery Fund
Bullish
2025 Q1
Invesco Discovery Fund
· 93 holdings
What the manager wrote
Bridgebio Pharma is a biotechnology company focused on rare diseases, especially heart-related conditions. The company’s lead drug was recently approved, and the launch has gone better than expected. This positive momentum in product launch positions Bridgebio favorably within the biotechnology sector, indicating strong growth potential as they address unmet medical needs in rare diseases.
Press Release
Articles on BridgeBio Pharma Inc
Headlines
See More- 1
Sep 01, 2026
Trump unveils new drug-pricing accords with CSL, Astellas, and other biotech drugmakers
Seeking Alpha • 11:10pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers